Financial Reports
As on December 31, 2024
Financial Summary 2024
Revenue
15,438,429 SR
Net Loss
(164,462,344) SR
Revenue
Industrial Investment, 15,438,429 SR
Profit from the activity
Medical Investment, (5,656,757) SR
Industrial Investment, 1,843,715 SR
Investment sector (12,847,399) SR
Discontinuous operations (159,115,417) SR
Assets
Liabilities and Shareholder Equity
2024 Milestones
Increasing the company's capital by offering priority rights shares.
Completion of all legal and financial studies related to the fundamental deal with Dallah Healthcare Company.
Helping subsidiaries' companies list their shares on the financial market.
Future Plans
The company's board of directors is working hard to re-assessment the company's investment strategy following the completion of the major transaction of selling its subsidiaries through one deal (Al-Ahsa Medical Services Company and Al-Salam Medical Services Company). The company is working to update its future investment plans to ensure they align with the aspirations of its shareholders, with a focus on promoting sustainable growth and enhancing the efficiency of financial performance, to achieve the highest returns for its shareholders.
Future Expectations
The company expects to complete the substantial deal with Dallah Healthcare Company in 2025.
The company is currently studying all available opportunities as it seeks to reformulate the company's investment strategies.
Structural changes
Completion of the capital increase process worth 200 million SAR through the offering of priority rights shares.
Signing of an acquisition and subscription agreement to sell all shares in Al-Ahsa Medical Services Company and Al-Salam Medical Services Company to Dallah Healthcare Company, with all required approvals obtained. Revenues and expenses of these subsidiaries were reclassified as discontinued operations.
Invitation to shareholders to vote on the amendment of the use of proceeds from the 200 million SAR priority rights offering.
Approval by the Capital Market Authority to register Tawariyat Medical Care Company (affiliate) for direct listing on the parallel market.
Sale of part of the company’s stake in the Arab Paper Manufacturing Company (Warak).
Opening of nominations for Board of Directors membership for the new three-year term starting 07/01/2025.
Clarification regarding the non-binding agreement between Al-Salam Medical Services Company and Aramco, confirming no material financial impact on the company’s operations.
For more information
You can download 2024 Board Director Report
Sign Up Newsletter
اشترك الان في قائمة الاخبار
Ayyan Investment Company is a Saudi joint–stock company with a Capital of SAR 1,006,363,280, established in 1993; to Invest, Establish & Own Industrial & Service-oriented Projects and Invest in Land & Real-estate Sectors.